查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
膀胱過度活動症治療市場：按藥物類別、疾病類型、分銷渠道分類：2021-2031 年全球機會分析和行業預測
市場調查報告書
商品編碼
1266397

膀胱過度活動症治療市場：按藥物類別、疾病類型、分銷渠道分類：2021-2031 年全球機會分析和行業預測

Overactive Bladder Treatment Market By Drug Class, By Diseases type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 268 Pages | 商品交期: 2-3個工作天內

價格

膀胱過度活動症治療市場在 2021 年的價值為 24.264 億美元，預計到 2031 年將達到 34.6522 億美元，從 2022 年到 2031 年的複合年增長率為 3.6%。

膀胱過度活動症 (OAB) 有時被定義為以一系列排尿症狀為特徵的疾病。 這種疾病會導致難以控制的頻繁和突然的排尿衝動。 您可能還會有白天和晚上多次小便的衝動。 另一個特點是無意中漏尿。 它影響兩性，但在女性中更為明顯。 症狀包括急迫且無法控制的排尿衝動、頻繁的不自主排尿和尿頻。 這些症狀對於醫療保健提供者來說很難診斷，因為它們因症狀和個體差異而異。 市場上有幾種治療膀胱過度活動症的藥物，可以放鬆膀胱並減輕 OAB 的症狀。

推動膀胱過度活動症治療市場增長的主要因素包括膀胱過度活動症發病率上升、膀胱結石和膀胱腫瘤患病率上升以及製藥領域研發活動的增加。您可以 膀胱過度活動症的發病率在全世界人口中顯著增加。 這種增加歸因於導致膀胱過度活動症的幾種情況的□□增加。 中風和多發性硬化症等神經系統疾病、導致尿頻或多尿的尿路感染、糖尿病和更年期婦女的荷爾蒙變化是導致膀胱過度活動症的一些主要因素。

例如，根據克利夫蘭診所 2022 年發表的一篇文章，膀胱過度活動症在美國是一種常見病，影響了多達 3300 萬成年人，其中包括 30% 的男性和 40% 的女性。包括 % 的人. 此外，前列腺肥大、便秘和治療尿失禁的手術史也是導致膀胱過度活動症的因素。 因此，大量導致膀胱過度活動症的因素的存在增加了全世界人群膀胱過度活動症的發病率。 因此，對治療藥物的需求不斷增加，進一步推動了膀胱過度活動症治療市場的增長。

此外，製藥領域研發活動的增加也推動了市場的增長。 近年來，針對各種疾病開發和創新新療法的研究活動變得非常活躍。 還正在進行研究以闡明膀胱過度活動症的病理學及其原因。 在深入研究的基礎上，科學家們開發出了針對膀胱過度活動症症狀的藥物和分子，為治療膀胱過度活動症提供了新的可能。 預計這將重振市場。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 頂級影響因子
    • 頂級投資基金
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭對手的實力
  • 市場動態
    • 司機
      • 增加膀胱過度活動症的發生率
      • 膀胱腫瘤和膀胱結石的患病率增加
      • 增加研發活動
    • 約束因素
      • 對治療膀胱過度活動症的新藥知之甚少
      • 與治療相關的副作用
    • 機會
      • 新興國家的增長機會
  • 分析 COVID-19 對市場的影響

第 4 章膀胱過度活動症治療市場：按藥物類別分類

  • 概覽
    • 市場規模和預測
  • 具有抗膽鹼能活性的藥物
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • β-3 腎上腺素能藥物
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 保妥適
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 5 章膀胱過度活動症治療市場：按疾病類型分類

  • 概覽
    • 市場規模和預測
  • 特發性膀胱過度活動症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 神經源性膀胱過度活動症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 6 章膀胱過度活動症治療市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 藥店和配藥店
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：國家/地區分析

第 7 章膀胱過度活動症治療市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按疾病類型
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
  • 歐洲
    • 主要趨勢和機會
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按疾病類型
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按疾病類型
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
  • 拉美
    • 主要趨勢和機會
    • 市場規模和預測：按藥物類別
    • 市場規模和預測：按疾病類型
    • 市場規模和預測：按分銷渠道
    • 市場規模/預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道
      • LAMEA 的其餘部分
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按藥物類別
      • 市場規模和預測：按疾病類型
      • 市場規模和預測：按分銷渠道

第八章競爭格局

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 定位頂級公司，2021 年

第九章企業概況

  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd
  • Teva Pharmaceutical Industries Limited
  • Cipla Ltd
  • Lupin
  • Sun Pharmaceutical Industries Ltd.
Product Code: A10543

The overactive bladder treatment market valued for $2,426.40 million in 2021 and is estimated to reach $3,465.22 million by 2031, exhibiting a CAGR of 3.6% from 2022 to 2031. 

Overactive bladder (OAB) may be defined as a condition which is characterized by a group of urinary symptoms. The condition causes a frequent and sudden urge to urinate which is difficult to control. Also, the person may feel an urge to urinate several times during the day as well as nighttime. It can also be characterized by unintentional loss of urine. Though it affects population of both genders but is more prominent in women. Its symptoms include urgent and uncontrollable need to urinate, frequent involuntary loss of urine, frequent urination, and others. These symptoms can be variable depending on the condition and the individual, which makes it difficult for the healthcare provider to diagnose the condition. Several medications are available in the market for treating the overactive bladder that can help relax the bladder and reduce symptoms of OAB.

Major factors driving the growth of overactive bladder treatment market include the rise in incidence of overactive bladder, increase in prevalence of bladder stones and bladder tumor, and increase in R&D activities in the pharmaceutical field. There is a huge rise in incidence of overactive bladder in the population around the globe. This rise is attributed to an increase in several pathological conditions causing overactive bladder. Neurological disorders such as stroke and multiple sclerosis, urinary tract infection that causes frequent and excessive urination, diabetes, and hormonal changes in women during menopause, are some of the major factors causing overactive bladder. 

For instance, according to an article published by Cleveland Clinic in 2022, overactive bladder is a common condition in the U.S., and it affects up to 33 million adults, which include as many as 30% men and 40% women. This boosts the growth of the overactive bladder treatment market.In addition, conditions such as enlarged prostate, constipation and previous surgery done to treat incontinence are also some of the factors causing overactive bladder. Thus, the presence of huge number of factors causing overactive bladder increases its incidences in population all around the globe. This increases the demand for treatment medications and further propels the growth of the overactive bladder treatment market.

Furthermore, the increase in R&D activities in the pharmaceutical field is boosting the growth of the market. In recent years there has been a huge rise in research activities to develop and innovate new treatment options for various diseases. Research has been carried out to discover more about the pathology of the overactive bladder and its causes. Based on detail study, drugs and molecules has been developed by the scientist to target symptoms and thus offer new entities for treatment of the condition. This is anticipated to boost the market.

In addition, investments have been made by the key market players to establish advanced manufacturing techniques for development of medication. This makes it possible for the key players to offer high quality medications to the customers, which increases its efficacy and positive results in the patient. This further raises its demand for the treatment of overactive bladder, and thus boosts the market growth. Also, key market players are shifting their focus towards emerging countries which are anticipated to expand the market during the forecast period. Investments in emerging countries will offer lucrative opportunities for the market growth owing to the increasing healthcare spending, presence of favorable government facilities, and presence of raw materials in abundance in this region. 

In addition, increasing healthcare expenditure and developing healthcare facilities in regions such as Asia-Pacific, is anticipated to boost the overactive bladder market during the forecast period.Although various key factors are driving the growth of the market, the presence of few factors such as lack of awareness about overactive bladder and some side effects associated with the medications is providing hindrance to the growth of the market. There is a very low awareness about the condition among the population in underdeveloped countries. People here are unaware about the condition and also its available treatment options. In addition, the presence of alternate treatment options such as pelvic floor physical therapy and surgery is also causing hindrance to the market growth. 

The overactive bladder treatment market is segmented by drug class, disease type, distribution channel and region. By drug class, the market is categorized into anti-cholinergic drugs, beta-3 adrenergic drugs, Botox, and others. On the basis of disease type, the market is segregated into idiopathic overactive bladder and neurogenic overactive bladder. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers. 

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major Key players that operate in the overactive bladder treatment market are AbbVie Inc., Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin, Pfizer Inc., Sumitomo Pharma Co., Ltd, Inc., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the overactive bladder treatment market analysis from 2021 to 2031 to identify the prevailing overactive bladder treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the overactive bladder treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global overactive bladder treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Anti-Cholinergic Drugs
  • Beta-3 adrenergic drugs
  • Botox
  • Others

By Diseases type

  • Idiopathic Bladder Overactivity
  • Neurogenic Bladder Overactivity

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Korea
    • Rest of LAMEA

Key Market Players

  • AbbVie Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Limited
  • Cipla Ltd
  • Lupin
  • Sumitomo Pharma Co., Ltd
  • Astellas Pharma Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Alembic Pharmaceuticals Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidences of overactive bladder
      • 3.4.1.2. Increase in prevalence of bladder tumors and bladder stones
      • 3.4.1.3. Increase in R&D activities
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of awareness regarding novel therapeutics for overactive bladder
      • 3.4.2.2. Side effects associated with the treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Anti-Cholinergic Drugs
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Beta-3 adrenergic drugs
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Botox
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Idiopathic Bladder Overactivity
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Neurogenic Bladder Overactivity
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: OVERACTIVE BLADDER TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Class
    • 7.2.3. Market size and forecast, by Diseases type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Class
      • 7.2.5.1.3. Market size and forecast, by Diseases type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Class
      • 7.2.5.2.3. Market size and forecast, by Diseases type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Class
      • 7.2.5.3.3. Market size and forecast, by Diseases type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Class
    • 7.3.3. Market size and forecast, by Diseases type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Class
      • 7.3.5.1.3. Market size and forecast, by Diseases type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Class
      • 7.3.5.2.3. Market size and forecast, by Diseases type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Class
      • 7.3.5.3.3. Market size and forecast, by Diseases type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Class
      • 7.3.5.4.3. Market size and forecast, by Diseases type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Class
      • 7.3.5.5.3. Market size and forecast, by Diseases type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Class
      • 7.3.5.6.3. Market size and forecast, by Diseases type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Class
    • 7.4.3. Market size and forecast, by Diseases type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Class
      • 7.4.5.1.3. Market size and forecast, by Diseases type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Class
      • 7.4.5.2.3. Market size and forecast, by Diseases type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Class
      • 7.4.5.3.3. Market size and forecast, by Diseases type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Class
      • 7.4.5.4.3. Market size and forecast, by Diseases type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Class
      • 7.4.5.5.3. Market size and forecast, by Diseases type
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Class
      • 7.4.5.6.3. Market size and forecast, by Diseases type
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Class
    • 7.5.3. Market size and forecast, by Diseases type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Class
      • 7.5.5.1.3. Market size and forecast, by Diseases type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Class
      • 7.5.5.2.3. Market size and forecast, by Diseases type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Korea
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Class
      • 7.5.5.3.3. Market size and forecast, by Diseases type
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Class
      • 7.5.5.4.3. Market size and forecast, by Diseases type
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Alembic Pharmaceuticals Limited
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Astellas Pharma Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Dr. Reddy's Laboratories Ltd.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Pfizer Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Sumitomo Pharma Co., Ltd
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Teva Pharmaceutical Industries Limited
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Cipla Ltd
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Lupin
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Sun Pharmaceutical Industries Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 02. OVERACTIVE BLADDER TREATMENT MARKET FOR ANTI-CHOLINERGIC DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. OVERACTIVE BLADDER TREATMENT MARKET FOR BETA-3 ADRENERGIC DRUGS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. OVERACTIVE BLADDER TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 07. OVERACTIVE BLADDER TREATMENT MARKET FOR IDIOPATHIC BLADDER OVERACTIVITY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROGENIC BLADDER OVERACTIVITY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 10. OVERACTIVE BLADDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. OVERACTIVE BLADDER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. OVERACTIVE BLADDER TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 19. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 20. U.S. OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 21. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 22. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 23. CANADA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 24. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 34. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 37. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 38. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 39. UK OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 40. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 41. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 42. ITALY OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 43. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 46. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 49. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 53. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 56. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 57. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 58. CHINA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 59. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 60. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 61. INDIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 71. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 75. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 78. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 84. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 87. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 91. ABBVIE INC.: KEY STRATERGIES
  • TABLE 92. ALEMBIC PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 93. ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 94. ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 95. ALEMBIC PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 96. ALEMBIC PHARMACEUTICALS LIMITED: KEY STRATERGIES
  • TABLE 97. ASTELLAS PHARMA INC.: KEY EXECUTIVES
  • TABLE 98. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 99. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
  • TABLE 100. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 101. ASTELLAS PHARMA INC.: KEY STRATERGIES
  • TABLE 102. DR. REDDY'S LABORATORIES LTD.: KEY EXECUTIVES
  • TABLE 103. DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 104. DR. REDDY'S LABORATORIES LTD.: PRODUCT SEGMENTS
  • TABLE 105. DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 106. DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
  • TABLE 107. PFIZER INC.: KEY EXECUTIVES
  • TABLE 108. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 109. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 110. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 111. SUMITOMO PHARMA CO., LTD: KEY EXECUTIVES
  • TABLE 112. SUMITOMO PHARMA CO., LTD: COMPANY SNAPSHOT
  • TABLE 113. SUMITOMO PHARMA CO., LTD: PRODUCT SEGMENTS
  • TABLE 114. SUMITOMO PHARMA CO., LTD: PRODUCT PORTFOLIO
  • TABLE 115. SUMITOMO PHARMA CO., LTD: KEY STRATERGIES
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 117. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 118. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 121. CIPLA LTD: KEY EXECUTIVES
  • TABLE 122. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 123. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 124. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 125. LUPIN: KEY EXECUTIVES
  • TABLE 126. LUPIN: COMPANY SNAPSHOT
  • TABLE 127. LUPIN: PRODUCT SEGMENTS
  • TABLE 128. LUPIN: PRODUCT PORTFOLIO
  • TABLE 129. LUPIN: KEY STRATERGIES
  • TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 131. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 132. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 133. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN OVERACTIVE BLADDER TREATMENT MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALOVERACTIVE BLADDER TREATMENT MARKET
  • FIGURE 10. OVERACTIVE BLADDER TREATMENT MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR ANTI-CHOLINERGIC DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR BETA-3 ADRENERGIC DRUGS, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 15. OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASES TYPE, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR IDIOPATHIC BLADDER OVERACTIVITY, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROGENIC BLADDER OVERACTIVITY, BY COUNTRY 2021-2031(%)
  • FIGURE 18. OVERACTIVE BLADDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF OVERACTIVE BLADDER TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 22. OVERACTIVE BLADDER TREATMENT MARKET BY REGION, 2021
  • FIGURE 23. U.S. OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. CANADA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. MEXICO OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. GERMANY OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. FRANCE OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. UK OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. ITALY OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SPAIN OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF EUROPE OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. JAPAN OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CHINA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. INDIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. REST OF LAMEA OVERACTIVE BLADDER TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: OVERACTIVE BLADDER TREATMENT MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2021
  • FIGURE 49. ABBVIE INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 51. ABBVIE INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. ALEMBIC PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 53. ASTELLAS PHARMA INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. DR. REDDY'S LABORATORIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. DR. REDDY'S LABORATORIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 59. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 60. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 61. SUMITOMO PHARMA CO., LTD: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. SUMITOMO PHARMA CO., LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. SUMITOMO PHARMA CO., LTD: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. CIPLA LTD: SALES REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 68. CIPLA LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 69. LUPIN: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 70. LUPIN: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 72. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)